Patient and Caregiver Perceptions of Advanced Bladder Cancer Systemic Treatments: Infodemiology Study Based on Social Media Data.
adverse event
attitude
bladder cancer
cancer
cancer treatment
caregiver
chemotherapy
first-line therapy
immunotherapy
oncology
opinion
patient
patient support
peer support
perception
pharmacotherapy
qualitative research
social media
Journal
JMIR cancer
ISSN: 2369-1999
Titre abrégé: JMIR Cancer
Pays: Canada
ID NLM: 101666844
Informations de publication
Date de publication:
27 Mar 2023
27 Mar 2023
Historique:
received:
20
12
2022
accepted:
02
03
2023
revised:
01
03
2023
medline:
28
3
2023
entrez:
27
3
2023
pubmed:
28
3
2023
Statut:
epublish
Résumé
In 2022, it was estimated that more than 80,000 new cases of bladder cancer (BC) were diagnosed in the United States, 12% of which were locally advanced or metastatic BC (advanced BC). These forms of cancer are aggressive and have a poor prognosis, with a 5-year survival rate of 7.7% for metastatic BC. Despite recent therapeutic advances for advanced BC, little is known about patient and caregiver perceptions of different systemic treatments. To further explore this topic, social media can be used to collect the perceptions of patients and caregivers when they discuss their experiences on forums and online communities. The aim of this study was to assess patient and caregiver perceptions of chemotherapy and immunotherapy for treating advanced BC from social media-posted data. Public posts on social media in the United States between January 2015 and April 2021 from patients with advanced BC and their caregivers were collected. The posts included in this analysis were geolocalized to the United States; collected from publicly available domains and sites, including social media sites such as Twitter and forums such as patient association forums; and were written in English. Posts mentioning any line of chemotherapy or immunotherapy were qualitatively analyzed by two researchers to classify perceptions of treatments (positive, negative, mixed, or without perception). A total of 80 posts by 69 patients and 142 posts by 127 caregivers mentioning chemotherapy, and 42 posts by 31 patients and 35 posts by 32 caregivers mentioning immunotherapy were included for analysis. These posts were retrieved from 39 public social media sites. Among patients with advanced BC and their caregivers, treatment perceptions of chemotherapy were more negative (36%) than positive (7%). Most of the patients' posts (71%) mentioned chemotherapy factually without expressing a perception of the treatment. The caregivers' perceptions of treatment were negative in 44%, mixed in 8%, and positive in 7% of posts. In combined patient and caregiver posts, immunotherapy was perceived positively in 47% of posts and negatively in 22% of posts. Caregivers also posted more negative perceptions (37%) of immunotherapy than patients (9%). Negative perceptions of both chemotherapy and immunotherapy were mainly due to side effects and perceived lack of effectiveness. Despite chemotherapy being standard first-line therapy for advanced BC, negative perceptions were identified on social media, particularly among caregivers. Addressing these negative perceptions of treatment may improve treatment adoption. Strengthening support for patients receiving chemotherapy and their caregivers to help them manage side effects and understand the role of chemotherapy in the treatment of advanced BC would potentially enable a more positive experience.
Sections du résumé
BACKGROUND
BACKGROUND
In 2022, it was estimated that more than 80,000 new cases of bladder cancer (BC) were diagnosed in the United States, 12% of which were locally advanced or metastatic BC (advanced BC). These forms of cancer are aggressive and have a poor prognosis, with a 5-year survival rate of 7.7% for metastatic BC. Despite recent therapeutic advances for advanced BC, little is known about patient and caregiver perceptions of different systemic treatments. To further explore this topic, social media can be used to collect the perceptions of patients and caregivers when they discuss their experiences on forums and online communities.
OBJECTIVE
OBJECTIVE
The aim of this study was to assess patient and caregiver perceptions of chemotherapy and immunotherapy for treating advanced BC from social media-posted data.
METHODS
METHODS
Public posts on social media in the United States between January 2015 and April 2021 from patients with advanced BC and their caregivers were collected. The posts included in this analysis were geolocalized to the United States; collected from publicly available domains and sites, including social media sites such as Twitter and forums such as patient association forums; and were written in English. Posts mentioning any line of chemotherapy or immunotherapy were qualitatively analyzed by two researchers to classify perceptions of treatments (positive, negative, mixed, or without perception).
RESULTS
RESULTS
A total of 80 posts by 69 patients and 142 posts by 127 caregivers mentioning chemotherapy, and 42 posts by 31 patients and 35 posts by 32 caregivers mentioning immunotherapy were included for analysis. These posts were retrieved from 39 public social media sites. Among patients with advanced BC and their caregivers, treatment perceptions of chemotherapy were more negative (36%) than positive (7%). Most of the patients' posts (71%) mentioned chemotherapy factually without expressing a perception of the treatment. The caregivers' perceptions of treatment were negative in 44%, mixed in 8%, and positive in 7% of posts. In combined patient and caregiver posts, immunotherapy was perceived positively in 47% of posts and negatively in 22% of posts. Caregivers also posted more negative perceptions (37%) of immunotherapy than patients (9%). Negative perceptions of both chemotherapy and immunotherapy were mainly due to side effects and perceived lack of effectiveness.
CONCLUSIONS
CONCLUSIONS
Despite chemotherapy being standard first-line therapy for advanced BC, negative perceptions were identified on social media, particularly among caregivers. Addressing these negative perceptions of treatment may improve treatment adoption. Strengthening support for patients receiving chemotherapy and their caregivers to help them manage side effects and understand the role of chemotherapy in the treatment of advanced BC would potentially enable a more positive experience.
Identifiants
pubmed: 36972135
pii: v9i1e45011
doi: 10.2196/45011
pmc: PMC10131927
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e45011Informations de copyright
©Simon Renner, Paul Loussikian, Pierre Foulquié, Alexia Marrel, Valentin Barbier, Adel Mebarki, Stéphane Schück, Murtuza Bharmal. Originally published in JMIR Cancer (https://cancer.jmir.org), 27.03.2023.
Références
J Med Internet Res. 2008 May 27;10(3):e15
pubmed: 18504244
World J Urol. 2016 Jan;34(1):57-62
pubmed: 26590917
Eur J Oncol Nurs. 2018 Aug;35:92-101
pubmed: 30057091
Oncologist. 2021 Feb;26(2):e342-e344
pubmed: 33210442
BMC Cancer. 2013 Oct 29;13:508
pubmed: 24168075
Eur Urol. 2023 Apr;83(4):320-328
pubmed: 35654659
BJU Int. 2018 Apr;121(4):549-557
pubmed: 28990272
Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8
pubmed: 25096609
Palliat Med. 2006 Dec;20(8):755-67
pubmed: 17148530
JMIR Cancer. 2022 Sep 20;8(3):e37518
pubmed: 36125861
Qual Life Res. 2020 Aug;29(8):2241-2252
pubmed: 32246432
Ophthalmol Ther. 2023 Feb;12(1):501-516
pubmed: 36502495
J Urol. 2014 Apr;191(4):937-42
pubmed: 24184369
Psychooncology. 2011 Dec;20(12):1342-52
pubmed: 22102594
Int J Med Inform. 2018 Mar;111:172-181
pubmed: 29425630
Qual Life Res. 2014 Oct;23(8):2153-67
pubmed: 24729055
J Cancer Surviv. 2017 Aug;11(4):453-461
pubmed: 28213769
Medicine (Baltimore). 2018 Sep;97(39):e11863
pubmed: 30278483
Bladder Cancer. 2015 Oct 26;1(2):151-158
pubmed: 27376115
Cancers (Basel). 2021 Jan 03;13(1):
pubmed: 33401585
J Med Internet Res. 2020 Jul 28;22(7):e16337
pubmed: 32720910
JCO Clin Cancer Inform. 2019 Mar;3:1-6
pubmed: 30860867
J Med Internet Res. 2020 Dec 7;22(12):e18767
pubmed: 33284127
J Med Internet Res. 2020 Sep 11;22(9):e19694
pubmed: 32915159
J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053
pubmed: 30181416
Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):139-46
pubmed: 24325545
BJU Int. 2019 May;123 Suppl 5:10-18
pubmed: 30801892